EU/3/13/1227

About

On 16 January 2014, orphan designation (EU/3/13/1227) was granted by the European Commission to Cell Medica Ltd., United Kingdom, for adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo, for the treatment of adenovirus infection in allogeneic haematopoietic stem cell transplant recipients.

The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlands, in February 2019.

Key facts

Active substance
Adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo
Disease / condition
Treatment of adenovirus infection in allogeneic haematopoietic stem cell transplant recipients
Date of first decision
16/01/2014
Outcome
Positive
EU designation number
EU/3/13/1227

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Clinical Network Services (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
The Netherlands
Tel. +31 2089 49169
E-mail: cns@clinical.net.au

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating